AIHTA - Publications - Search - Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma. Fact Sheet Nr. 188.

[thumbnail of Fact Sheet Nr.188.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
376kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 400-600 Ureter. Bladder. Urethra
Language:English
Series Name:Fact Sheet Nr. 188
Deposited on:24 Sep 2024 10:46
Last Modified:24 Sep 2024 10:46

Repository Staff Only: item control page